TECHNICAL INFORMATION

• For optimum results when using the online submission system, it is recommended to use one of the following browsers: Google Chrome, Mozilla FireFox or Safari.
• Please note that in rare cases you may encounter an issue copy/pasting from Word on Mac, triggering an error message that your title cannot exceed 1,000 characters. In this case please reload the page and either type or copy/paste the title from a plain text application.
• JavaScripts and cookies need to be enabled in your browser. Instructions to enable cookies are given on the login page.

ACCOUNT MANAGEMENT - PERSONAL INFORMATION

Note: If you created an abstract submission account from 2021 onwards, please use this account.

• The creation of a user account is required for the submission of an abstract. The account only needs to be created once (also if you choose to submit more than one abstract) and can be re-used for future EANO abstract submissions.
• By using the username and password you created you will be able to return and edit, delete or withdraw your abstract at a later stage.
• Personal information can be edited if necessary by clicking the „Profile“ icon (e.g. in case of an address change). Attention: All correspondence regarding the acceptance of your abstract will be emailed to the address given by you in the „author section“. Please provide a working email address.

First time users:

1. When entering the online submission portal, click on „Create new account“. Fill in all required fields and save your personal information by clicking “Save & Continue” in the online form.
   Note: Please remember to create a password not being used for other logins (i.e. bank accounts, market places etc.)
2. Once you have logged into the submission portal, you will be directed to the abstract submission site. Click on the “+New” button to start your abstract submission. If you cannot see this button, please make sure you are located in the tab labelled “submissions”.
3. When clicking the “+New” button a new tab will open in your browser. Follow step by step the instructions for submission.
4. At the end of the process, you will see a summary of your submission (“Review my work“). After submitting your abstract it should show as complete on your submission site.

Returning users submitting a new abstract:

1. Login with the username and password you created.
2. Click on the “+New” button to start a new submission.
3. Carefully follow the step-by-step instructions.

Returning users continuing an aborted submission or editing an abstract already submitted:

1. Login with the username and password you created.
2. Locate the abstract and click on the displayed abstract title to make changes or complete the abstract.
3. Continue your submission or click on the menu item you wish to change.
4. Changes can be made until the submission deadline.

New in 2024! We are aiming to publish full manuscripts of selected major content simultaneously with the oral presentation at the EANO Meeting in Neuro-Oncology.

Please indicate your preference for your abstract to be evaluated for this opportunity by using the appropriate tick box during the submission process (SUBMISSION STEP 8: MORE INFORMATION).

With the submission of an abstract to the EANO Meeting the presenting author:

• confirms that all authors are aware of and agree to the content of the abstract and support the data presented and that no other regular abstract of the same content has been submitted via this abstract submission process;
• accepts to be the contact person for all correspondence about the abstract and to inform co-authors and especially the presenting author about its status;
• acknowledges that at least the presenting author of the abstract must register and pay the registration fee by July 31, 2024, otherwise the abstract will be rejected. ATTENTION: The regular registration payment period of 2 weeks does not apply in this case. This deadline also applies to presenting authors with a free registration;
• states that for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority, and properly informed consent give where appropriate;
• accepts responsibility for the accuracy of the submitted abstract;
• acknowledges that once the abstract has been submitted, changes, corrections or rewordings are only possible until the deadline of abstract submission (July 2, 2024);
• acknowledges that no corrections / withdrawals are possible after July 31, 2024;
• agrees that the abstract submission is not possible without collecting, saving and processing her/his personal data. This is done in accordance with the most recent legislation on data protection (EU-GDPR 2018) and solely for the purpose of organising and realising the event. All abstracts including the author block will be published within the electronic abstract book published in the Journal Neuro-Oncology by Oxford University Press and on the website as well as in the EANO congress mobile app, which will be made accessible to all participants, committee members and sponsors (detailed data protection regulations);
• understands that the abstract submission system as well as the publication process is operated by USA based companies (CTI, Oxford University Press).
• acknowledges that careful typing and proof-reading are essential as the abstract will appear, if accepted, as submitted;
• warrants that in case she/he submits a regular abstract, the data and conlusions presented in the abstract have not been published prior to the date of the EANO meeting. Otherwise she/he has to submit either an “encore abstract” or a “trial in progress abstract”. Regular abstracts containing previously published material will be rejected;
• confirms that no person employed by a company as defined by the CMSS Code for Interactions with Companies is the first or presenting author on clinical abstracts or on abstracts on translational research from clinial trials;
• acknowledges that employees of pharmaceutical and diagnostic companies can submit and present data generated in in-vitro and pre-clinical basic research, but not of translational research from clinical trials. The meeting presentation, whether oral or poster, must clearly describe all financial disclosures.